Systematic review and meta-analysis of Saccharomyces boulardii in adult patients

Table 2 Randomized, controlled trials for the prevention of antibiotic associated diarrhea (AAD) using S. boulardii

Ref.	Treatment groups	Population	Daily dose: cfu/d (mg/d)	Duration (d)	Follow-up (wk)	AAD in S. boularii (%)	AAD in controls (%)
Adam et al[37]	S. boulardii vs placebo	388 hospitalized adults, multisite	4 × 109 (200 mg)	7	0	9/199 (4.5)a	33/189 (17.5)
Monteiro et al[55]	S. boulardii vs placebo	240 adults, Portugal	(nr) 4 caps/d	6	0	19/121 (15.7)a	33/119 (27.7)
Surawicz et al[58]	S. boulardii vs placebo	180 hospitalized adults at one hospital, Washington	2 × 1010 (1000 mg)	abx + 14 d	2-3	11/116 (9.5)a	14/64 (21.8)
McFarland et al[54]	S. boulardii vs placebo	193 hospitalized adults (1 or more beta-lactam antibiotics), 4 hospitals	2 × 1010 (1000 mg)	abx + 3 d	7	7/97 (7.2)a	14/96 (14.6)
Lewis et al[133]	S. boulardii vs placebo	72 enrolled, 69 done; elderly patients	4.5 × 109 (226 mg)	14	0	7/33 (21)	5/36 (13.9)
Cremonini et al[134]	S. boulardii vs placebo	43 H. pylori + adults on triple therapy	5 × 109 (nr)	14	2	1/22 (5)a	6/21 (30)
Duman et al[44]	S. boulardii vs placebo	389 adults in Turkey with H. pylori + peptic ulcers, all received triple therapy	2 × 1010 (1000 mg)	14	4	14/204 (6.9)a	28/180 (15.6)
Can et al[135]	S. boulardii vs placebo	151 adult inpatients	1 × 1010 (500 mg)	abx	4	1/73 (1.4)a	7/78 (9.0)
Cindoruk et al[42]	S. boulardiivs placebo	124 adults with H. pylori + dyspepsia	2 × 1010 (1000 mg)	14	6	9/62 (14.5)a	19/62 (30.6)
Bravo et al[136]	S. boulardiivs placebo	89 adult outpatients on amoxicillin	1 × 1010 (500 mg)	12	9	3/41 (7.3)	5/45 (11.1)

^aP < 0.05, probiotic vs controls. cfu: Colony forming unit; nr: Not reported; abx: Antibiotics.